Kv7 channels: Interaction with dopaminergic and serotonergic neurotransmission in the CNS

Journal of Physiology

Volumn 586, Issue 7, 2008, Pages 1823-1832

  Hansen, Henrik H ^a   Waroux, Olivier ^b   Seutin, Vincent ^b   Jentsch, Thomas J ^c   Aznar, Susana ^d   Mikkelsen, Jens D ^a,e  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Mental Health Services CPH   (Denmark)

^e AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS(2 FLUORO 4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; DOPAMINE; FLUPIRTINE; GLUTAMIC ACID; LINOPIRDINE; MUSCARINIC M1 RECEPTOR; NORADRENALIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KV7.2; POTASSIUM CHANNEL KV7.3; POTASSIUM CHANNEL KV7.4; POTASSIUM CHANNEL KV7.5; POTASSIUM CHANNEL STIMULATING AGENT; PROTEIN C FOS; RETIGABINE; SEROTONIN; FLINDOKALNER; POTASSIUM CHANNEL BLOCKING AGENT;

4 AMINOBUTYRIC ACID RELEASE; ACETYLCHOLINE RELEASE; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; BRAIN STEM; CATALEPSY; CELLULAR DISTRIBUTION; CHRONIC PAIN; COMPLEX PARTIAL SEIZURE; CONFERENCE PAPER; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ABUSE; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EPILEPSY; HUMAN; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL MEMBRANE STEADY POTENTIAL; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; TRANQUILIZING ACTIVITY; CELL MEMBRANE POTENTIAL; CENTRAL NERVOUS SYSTEM; PHYSIOLOGY; REVIEW; SYNAPTIC TRANSMISSION; ANXIETY; ARTICLE; BASAL GANGLION; CHANNEL GATING; CORPUS STRIATUM; FIRING RATE; GABAERGIC TRANSMISSION; MEDIAN RAPHE NUCLEUS; MEMBRANE POTENTIAL; NERVE CELL EXCITABILITY; NEUROTRANSMITTER RELEASE; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

CENTRAL NERVOUS SYSTEM; DOPAMINE; HUMANS; KCNQ POTASSIUM CHANNELS; MEMBRANE POTENTIALS; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 45549093780     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2007.149450     Document Type: Conference Paper

References (50)

1. Amat J, Baratta MV, Paul E, Bland ST, Watkins LR & Maier SF (2005). Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 8, 365-371.
2. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ & Steinlein OK (1998). A potassium channel mutation in neonatal human epilepsy. Science 279, 403-406.
3. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD & Blackburn-Munro RE (2005). Retigabine: Chemical synthesis to clinical application. CNS Drug Rev 11, 1-20.
4. Bonjean M, Waroux O, Dang-Vu T, Phillips C, Lamy C, Scuvee-Moreau J, Sepulchre R, Maquet P & Seutin V (2007). Effect of the M-current on the excitability of midbrain dopaminergic neurons: A computational study. 2007 Abstract Viewer/Itinerary Planner, Program No. 681.6. Society for Neuroscience, Washington, DC.
5. Cooper EC, Harrington E, Jan YN & Jan LY (2001). M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J Neurosci 21, 9529-9540.
6. Dalby-Brown W, Hansen HH, Korsgaard MP, Mirza N & Olesen SP (2006). K v 7 channels: Function, pharmacology and channel modulators. Curr Top Med Chem 6, 999-1023.
7. Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF & Campeau S (2004). Differential expression of 5HT-1A, α1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, γ-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J Comp Neurol 474, 364-378.
8. Delmas P & Brown DA (2005). Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6, 850-862.
9. + channel. J Neurosci 24, 1236-1244.
10. Edelbauer H, Lechner SG, Mayer M, Scholze T & Boehm S (2005). Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin. J Neurochem 93, 1110-1121.
11. Gartside SE, Hajos-Korcsok E, Bagdy E, Harsing LG Jr, Sharp T & Hajos M (2000). Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 98, 295-300.
12. Geiger J, Weber YG, Landwehrmeyer B, Sommer C & Lerche H (2006). Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neurosci Lett 400, 101-104.
13. Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Kruger J & Mikkelsen JD (2007). The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 570, 77-88.
14. Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Rønn LC, Waroux O, Scuvee-Moreau J, Seutin V & Mikkelsen JD (2006). The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 318, 1006-1019.
15. Harley CW (2007). Norepinephrine and the dentate gyrus. Prog Brain Res 163, 299-318.
16. Hu H, Vervaeke K & Storm JF (2007). M-channels (Kv7/KCNQ channels) that regulate synaptic integration, excitability, and spike pattern of CA1 pyramidal cells are located in the perisomatic region. J Neurosci 27, 1853-1867.
17. Jensen HS, Grunnet M & Olesen SP (2007). Inactivation as a new regulatory mechanism for neuronal Kv7 channels. Biophys J 92, 2747-2756.
18. Jentsch TJ (2000). Neuronal KCNQ potassium channels: Physiology and role in disease. Nat Rev Neurosci 1, 21-30.
19. 2 channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A 97, 4333-4338.
20. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D & Mirza NR (2005). Anxiolytic effects of maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 314, 282-292.
21. Koyama S & Appel SB (2006). Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 96, 535-543.
22. Koyama S, Brodie MS & Appel SB (2007). Ethanol inhibition of m-current and ethanol-induced direct excitation of ventral tegmental area dopamine neurons. J Neurophysiol 97, 1977-1985.
23. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El Amraoui A, Marlin S, Petit C & Jentsch TJ (1999). KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96, 437-446.
24. Lawrence JJ, Saraga F, Churchill JF, Statland JM, Travis KE, Skinner FK & McBain CJ (2006). Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons. J Neurosci 26, 12325-12338.
25. 2 channels. J Physiol 553, 789-802.
26. 2 receptors and KCNQ channels. Pflugers Arch 446, 684-694.
27. Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J & Shekhar A (2005). Modulation of anxiety circuits by serotonergic systems. Stress 8, 233-246.
28. Maier SF & Watkins LR (2005). Stressor controllability and learned helplessness: The roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 29, 829-841.
29. Marrion NV (1997). Control of M-current. Annu Rev Physiol 59, 483-504.
30. Martire M, Castaldo P, D'Amico M, Preziosi P, Annunziato L & Taglialatela M (2004). M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci 24, 592-597.
31. 3 H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. J Neurochem 102, 179-193.
32. Mikkelsen JD (2004). The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat. Neurosci Lett 362, 240-243.
33. Overton PG & Clark D (1997). Burst firing in midbrain dopaminergic neurons. Brain Res Brain Res Rev 25, 312-334.
34. Peters HC, Hu H, Pongs O, Storm JF & Isbrandt D (2005). Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci 8, 51-60.
35. Piccinin S, Randall AD & Brown JT (2006). KCNQ/Kv7 channel regulation of hippocampal gamma-frequency firing in the absence of synaptic transmission. J Neurophysiol 95, 3105-3112.
36. Pickel VM, Chan J & Nirenberg MJ (2002). Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions. Synapse 45, 113-124.
37. Schmidt WJ, Schuster G, Wacker E & Pergande G (1997). Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 327, 1-9.
38. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C & Jentsch TJ (2000). KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 275, 24089-24095.
39. + channels causes epilepsy. Nature 396, 687-690.
40. + channels involved in epilepsy. J Biol Chem 275, 13343-13348.
41. Seutin V, Scuvee-Moreau J, Giesbers I, Massotte L & Dresse A (1990). Effect of BHT 920 on monoaminergic neurons of the rat brain: An electrophysiological in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 342, 502-507.
42. Shen W, Hamilton SE, Nathanson NM & Surmeier DJ (2005). Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci 25, 7449-7458.
43. Soldovieri MV, Cilio MR, Miceli F & Bellini G, Miraglia del Giudice E, Castaldo P, Hernandez CC, Shapiro MS, Pascotto A, Annunziato L & Taglialatela M (2007). Atypical gating of M-type potassium channels conferred by mutations in uncharged residues in the S4 region of KCNQ2 causing benign familial neonatal convulsions. J Neurosci 27, 4919-4928.
44. Tatulian L & Brown DA (2003). Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 549, 57-63.
45. Tatulian L, Delmas P, Abogadie FC & Brown DA (2001). Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21, 5535-5545.
46. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE & McKinnon D (1998). KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science 282, 1890-1893.
47. Weber YG, Geiger J, Kampchen K, Landwehrmeyer B, Sommer C & Lerche H (2006). Immunohistochemical analysis of KCNQ2 potassium channels in adult and developing mouse brain. Brain Res 1077, 1-6.
48. Yamada H, Matsumoto N & Kimura M (2004). Tonically active neurons in the primate caudate nucleus and putamen differentially encode instructed motivational outcomes of action. J Neurosci 24, 3500-3510.
49. Yue C & Yaari Y (2004). KCNQ/M channels control spike afterdepolarization and burst generation in hippocampal neurons. J Neurosci 24, 4614-4624.
50. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH & Earl RA (1998). Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: Comparison to linopirdine. J Pharmacol Exp Ther 285, 724-730.